Maha Katabi

Maha Katabi, PhD, CFA is a General Partner of Sofinnova Investments. She is an experienced investor with over two decades in managing public and private biotech companies through bull and bear markets. She is currently a board member of ARTBIO, Marea, Quanta, Star, and Vera (VERA). Most recently Maha was a board member of Aiolos (acquired by GSK) and RayzeBio (RYZB: acquired by BMS), in addition to Amplyx (acquired by Pfizer), Gyroscope (acquired by Novartis) and Northsea. Prior to joining Sofinnova, Maha was a Managing Partner of Oxalis Capital and Partner at Sectoral Asset Management. She started her career in venture as a principal investor with associate and principal roles at T2C2/Bio and Ventures West. Maha serves as an advisor to amplify HERscience, a Yale Ventures initiative.

She is Board Chair of Exactis Innovation, a not-for-profit research network for precision oncology operating a data analytics platform to provide real world evidence data to clinical researchers and payors.

She received a Ph.D. in Pharmacology and a B.Sc. in Biology at McGill University and is a CFA charterholder.